keyword
MENU ▼
Read by QxMD icon Read
search

Mirabegron

keyword
https://www.readbyqxmd.com/read/29787370/how-long-do-we-have-to-treat-overactive-bladder-syndrome-oab-a-questionnaire-survey-of-canadian-urologists-and-gynecologists
#1
Mikolaj Przydacz, Lysanne Campeau, Jens-Erik Walter, Jacques Corcos
INTRODUCTION: Overactive bladder syndrome (OAB) is a highly prevalent and costly condition worldwide with negative impact on health-related quality of life. Although many guidelines exist and anticholinergics are considered to be the mainstay of pharmacological treatment, data are lacking regarding optimal treatment duration. Therefore, the aim of this study was to determine practice patterns of Canadian urologists and gynecologists regarding duration of OAB pharmacotherapy. METHODS: A 14-question survey was designed and survey links (English and French) were sent by email to all practicing urologists and gynecologists registered with the Canadian Urological Association and the Society of Obstetricians and Gynecologists of Canada via the associations' email lists...
May 14, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29783600/re-long-term-treatment-with-the-beta-3-adrenocepter-agonist-mirabegron-ameliorates-detrusor-overactivity-and-restores-cyclic-adenosine-monophosphate-camp-levels-in-obese-mice
#2
https://www.readbyqxmd.com/read/29777865/a-prospective-non-interventional-registry-study-of-patients-initiating-a-course-of-drug-therapy-for-overactive-bladder-perspective-rationale-design-and-methodology
#3
Eric S Rovner, Kevin V Carlson, Anna S Deal, Kavita V Nair, Eva E Oakkar, Julie Park, Eric Gemmen, Rita M Kristy, Katherine L Gooch, Carol R Schermer
INTRODUCTION: Pharmacotherapy of overactive bladder (OAB) typically involves treatment with an antimuscarinic or mirabegron, a β3-adrenoceptor agonist, but real-world evidence on their use, including treatment access, persistence, and switching, is limited. Here, we describe the design of a prospective, multicenter, non-interventional registry of patients beginning a new course of OAB pharmacological therapy in routine clinical practice. METHODS: Adults with an OAB diagnosis for at least 3 months who either initiated a new course of mirabegron or antimuscarinic, or who switched therapy were enrolled into PERSPECTIVE (A Prospective, Non-intErventional Registry Study of Patients Initiating a Course of Drug Therapy for OveractIVE Bladder)...
May 16, 2018: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/29772697/structure-activity-relationships-based-on-3d-qsar-comfa-comsia-and-design-of-aryloxypropanol-amine-agonists-with-selectivity-for-the-human-%C3%AE-3-adrenergic-receptor-and-anti-obesity-and-anti-diabetic-profiles
#4
Marcos Lorca, Cesar Morales-Verdejo, David Vásquez-Velásquez, Juan Andrades-Lagos, Javier Campanini-Salinas, Jorge Soto-Delgado, Gonzalo Recabarren-Gajardo, Jaime Mella
The wide tissue distribution of the adrenergic β3 receptor makes it a potential target for the treatment of multiple pathologies such as diabetes, obesity, depression, overactive bladder (OAB), and cancer. Currently, there is only one drug on the market, mirabegron, approved for the treatment of OAB. In the present study, we have carried out an extensive structure-activity relationship analysis of a series of 41 aryloxypropanolamine compounds based on three-dimensional quantitative structure-activity relationship (3D-QSAR) techniques...
May 16, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29724504/mirabegron-versus-antimuscarinics-in-the-treatment-of-overactive-bladder-the-final-answer
#5
EDITORIAL
Tom A T Marcelissen, Gommert A Van Koeveringe
No abstract text is available yet for this article.
April 30, 2018: European Urology
https://www.readbyqxmd.com/read/29699858/efficacy-and-tolerability-of-mirabegron-compared-with-antimuscarinic-monotherapy-or-combination-therapies-for-overactive-bladder-a-systematic-review-and-network-meta-analysis
#6
Con Kelleher, Zalmai Hakimi, Richard Zur, Emad Siddiqui, Khaled Maman, Samuel Aballéa, Jameel Nazir, Chris Chapple
BACKGROUND: Mirabegron is an established treatment alternative to antimuscarinic therapy for patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase III trials. OBJECTIVE: To assess efficacy and tolerability of mirabegron 50mg versus antimuscarinic monotherapies and combination therapies. DESIGN, SETTING, AND PARTICIPANTS: Systematic literature review and network meta-analysis of randomised controlled trials (2000-2017) assessing eligible treatments for OAB...
April 23, 2018: European Urology
https://www.readbyqxmd.com/read/29697209/efficacy-and-safety-of-mirabegron-a-%C3%AE-3-adrenoceptor-agonist-in-patients-with-detrusor-hyperactivity-and-impaired-contractility
#7
Cheng-Ling Lee, Hann-Chorng Kuo
OBJECTIVE: We examined the efficacy and safety of mirabegron in elderly patients with urodynamic detrusor hyperactivity with impaired contractility (DHIC). METHODS: Patients diagnosed with DHIC received daily dose of mirabegron (25mg). Subjective symptom scores, uroflowmetry data, and adverse events (AEs) were recorded for all patients at baseline and after 1, 3, and 6 months treatment. Comparisons were made for each patient individually and between patients with detrusor overactivity (DO)...
April 26, 2018: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/29682790/trends-in-the-use-of-older-overactive-bladder-agents-and-uptake-of-fesoterodine-and-mirabegron-in-canada
#8
Rajwant Minhas, Mina Tadrous, Dean Elterman, Tara Gomes
AIMS: To examine early trends in the use of overactive bladder (OAB) agents across Canada, with a focus on initial uptake and reimbursement of two newer agents: fesoterodine, an anticholinergic, and mirabegron, a therapeutically novel beta-3 agonist. METHODS: We conducted a population-based cross-sectional study of outpatient prescriptions for long-acting oral OAB agents dispensed to individuals in Canada between May 2010 and April 2015 to examine the differences in the uptake of the newer agents and their reimbursement through cash, private, and public payers...
April 23, 2018: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/29680480/the-receipt-of-industry-payments-is-associated-with-prescribing-promoted-alpha-blockers-and-overactive-bladder-medications
#9
Parth K Modi, Ye Wang, Peter S Kirk, James M Dupree, Eric A Singer, Steven L Chang
OBJECTIVE: To determine the impact of physicians' financial relationships with the pharmaceutical industry on prescribing marketed alpha-blockers and overactive bladder medications. We also aim to examine if the number or total value of transactions is influential. MATERIALS AND METHODS: We linked the Open Payments Program database of industry payments to prescribers with Medicare Part D prescription data. We used binomial logistic regression to identify the association between receipt of industry payment and prescribing of marketed alpha-blockers (silodosin) and overactive bladder (OAB) medications (fesoterodine, solifenacin, and mirabegron)...
April 19, 2018: Urology
https://www.readbyqxmd.com/read/29673355/patient-reported-outcomes-in-patients-with-overactive-bladder-treated-with-mirabegron-and-tolterodine-in-a-prospective-double-blind-randomized-two-period-crossover-multicenter-study-prefer
#10
Sender Herschorn, David Staskin, Le Mai Tu, Jonathan Fialkov, Terry Walsh, Katherine Gooch, Carol R Schermer
BACKGROUND: The PREFER study was an assessment of medication tolerability, treatment preference and symptom improvement during treatment with mirabegron (M) and tolterodine (T) extended release (ER) in patients with overactive bladder (OAB). In this analysis of PREFER, patient-reported outcomes (PROs) were assessed during treatment. METHODS: PREFER was a two-period, 8-week crossover, double-blind, phase IV study (NCT02138747) of treatment-naïve adults with OAB ≥3 months randomized to 1 of 4 treatment sequences (M/T; T/M; M/M; T/T), separated by a 2-week washout...
April 19, 2018: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/29665997/lower-urinary-tract-symptoms-what-s-new-in-medical-treatment
#11
REVIEW
Benoit Peyronnet, Benjamin M Brucker, Martin C Michel
CONTEXT: Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). OBJECTIVE: To review emerging evidence in the medical treatment of LUTS. EVIDENCE ACQUISITION: An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS...
April 14, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29651798/long-term-persistence-with-mirabegron-in-a-real-world-clinical-setting
#12
Naoki Wada, Masaki Watanabe, Hiroko Banjo, Miyu Tsuchida, Junichi Hori, Gaku Tamaki, Makoto Azumi, Masafumi Kita, Hidehiro Kakizaki
OBJECTIVES: To examine the long-term persistence rate with mirabegron in a real-world clinical setting. METHODS: We retrospectively collected the data of patients who were prescribed mirabegron. We investigated the persistence rate and the reason for the discontinuation. The analysis included patient's age, diagnosis, Overactive Bladder Symptom Score, prostatic volume, the prescription by specialists for lower urinary tract dysfunction, drug-naïve patients, replacement of antimuscarinics or add-on therapy to antimuscarinics...
April 12, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29645285/cardiovascular-safety-of-the-%C3%AE-3-adrenoceptor-agonist-mirabegron-and-the-antimuscarinic-agent-solifenacin-in-the-synergy-trial
#13
William B White, Christopher Chapple, Christian Gratzke, Sender Herschorn, Dudley Robinson, Jeffrey Frankel, Arwin Ridder, Matthias Stoelzel, Asha Paireddy, Robert van Maanen, Michael A Weber
There have been concerns that treatment of overactive bladder with β3 -adrenoceptor agonists may potentially have detrimental cardiovascular (CV) side effects. We evaluated the CV safety of mirabegron, a β3 -adrenoceptor agonist, alone and in combination therapy with the antimuscarinic agent solifenacin. The SYNERGY trial was a multinational, multicenter, randomized, double-blind, parallel-group, placebo and active-controlled phase 3 trial. Patients were randomized to receive solifenacin 5 mg + mirabegron 50 mg (combination 5 + 50 mg), solifenacin 5 mg + mirabegron 25 mg (combination 5 + 25 mg), solifenacin 5 mg monotherapy, mirabegron 25 mg monotherapy, mirabegron 50 mg monotherapy, or placebo for a 12-week double-blind treatment period...
April 12, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29644100/persistent-urine-leakage-around-a-suprapubic-catheter-the-experience-of-a-person-with-chronic-tetraplegia
#14
Subramanian Vaidyanathan, Jerry Ward, Bakul M Soni, Peter Hughes, Tun Oo
Introduction: Persistent urine leakage after suprapubic cystostomy in tetraplegic subjects occurs due to shrinkage of the urinary bladder and bladder spasms. The patient's social life is adversely affected as clothes become wet, smelly, and require frequent changing, thus increasing the workload of carers. Case presentation: A 48-year-old male sustained C-4 complete (AIS:A) tetraplegia while swimming in 2007. Suprapubic cystostomy was performed in 2009. From 2012, this patient had urine leakage around the suprapubic catheter, which became progressively more frequent...
2018: Spinal Cord Series and Cases
https://www.readbyqxmd.com/read/29625926/oral-pharmacologic-management-of-overactive-bladder-syndrome-where-do-we-stand
#15
REVIEW
Tom Marcelissen, Tina Rashid, Tiago Antunes Lopes, Nicolas Barry Delongchamps, Bogdan Geavlete, Malte Rieken, Jean-Nicolas Cornu, Mohammad Sajjad Rahnama'i
Overactive bladder syndrome (OAB) is a prevalent disorder with a significant impact on quality of life. Despite this high prevalence, there is significant underdiagnosis and undertreatment due to several barriers, including embarrassment, poor communication and low patient adherence. Currently, various antimuscarinic are available in the treatment of OAB. The introduction of mirabegron has broadened the therapeutic approach and combination therapy of both agents can be valuable in clinical practice. Yet, patient adherence to most drugs for OAB is still relatively poor...
April 3, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29603781/efficacy-and-safety-of-mirabegron-for-the-treatment-of-neurogenic-detrusor-overactivity-prospective-randomized-double-blind-placebo-controlled-study
#16
Jan Krhut, Vladimír Borovička, Karolína Bílková, Radek Sýkora, David Míka, Jan Mokriš, Roman Zachoval
AIMS: To assess the efficacy and safety of mirabegron in the treatment of neurogenic detrusor overactivity. METHODS: This prospective, multicenter, randomized, double-blind, placebo-controlled study was conducted in three tertiary centers, and included 78 patients suffering from spinal cord injury or multiple sclerosis. Patients were randomized for Mirabegron 50 mg (Group A) or placebo (Group B). Urodynamic parameters, the 24 h pad-weight test, and patient-reported outcomes were assessed...
March 31, 2018: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/29578880/a-strategy-utilizing-ambulatory-monitoring-and-home-and-clinic-blood-pressure-measurements-to-optimize-the-safety-evaluation-of-noncardiovascular-drugs-with-potential-for-hemodynamic-effects-a-report-from-the-synergy-trial
#17
Michael A Weber, Christopher R Chapple, Christian Gratzke, Sender Herschorn, Dudley Robinson, Jeffrey M Frankel, Arwin M Ridder, Matthias Stoelzel, Asha Paireddy, Robert van Maanen, William B White
OBJECTIVE: The aim of this study was to perform a blood pressure (BP) safety evaluation in patients with an overactive bladder receiving solifenacin (an antimuscarinic agent), mirabegron (a β3-adrenoceptor agonist), or both compared with placebo in the SYNERGY trial. PATIENTS AND METHODS: Patients were randomized to receive solifenacin 5 mg+mirabegron 50 mg (combination 5+50 mg); solifenacin 5 mg+mirabegron 25 mg (combination 5+25 mg); solifenacin 5 mg; mirabegron 50 mg; mirabegron 25 mg; or placebo for a double-blind 12-week treatment period...
March 23, 2018: Blood Pressure Monitoring
https://www.readbyqxmd.com/read/29562093/investigation-of-mechanistic-pathway-for-trimethyl-borate-mediated-amidation-of-r-mandelic-acid-for-the-synthesis-of-mirabegron-an-antimuscarinic-agent
#18
Dattatray G Deshmukh, Mukund N Bangal, Mukunda R Patekar, Vijay J Medhane, Vijayavitthal Thippannachar Mathad
The present work describes investigation of mechanistic pathway for trimethyl borate mediated amidation of (R)-mandelic acid (3) with 4-nitophenylethylamine (2) to provide (R)-2-hydroxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide (4) during mirabegron synthesis. Plausible reaction mechanism is proposed by isolating and elucidating the active α-hydroxy ester intermediate 16 from the reaction mass. Trimethyl borate mediated approach proved to be selective in providing 4 without disturbing α-hydroxyl group and stereochemistry of the chiral center, and is also a greener, more economic and production friendly over the reported methods...
March 2018: Acta Chimica Slovenica
https://www.readbyqxmd.com/read/29556972/mirabegron-is-alternative-to-antimuscarinic-agents-for-overactive-bladder-without-higher-risk-in-hypertension-a-systematic-review-and-meta-analysis
#19
Hsiao-Ling Chen, Tun-Chieh Chen, Hsiu-Mei Chang, Yung-Shun Juan, Wei-Hsuan Huang, Hung-Fang Pan, Yong-Chieh Chang, Chiou-Mei Wu, Ya-Ling Wang, Hsiang Ying Lee
PURPOSE: Mirabegron, a β3-adrenoceptor agonist, was approved for overactive bladder (OAB), but worsened hypertension was a potential risk based on its mechanism of action. Besides, head to head comparisons were limited between mirabegron and antimuscarinic agents, the prior first-line pharmacotherapy of OAB. In this regard, we performed a systematic review and meta-analysis to compare their efficacy as well as safety, especially in blood pressure changes. MATERIALS AND METHODS: Literature search was conducted in PubMed, Medline and seven randomized clinical trial (RCT) register databases of WHO, EU, USA, Taiwan, China, Japan and Cochrane...
March 19, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29542337/cardiovascular-effects-of-antimuscarinic-agents-and-beta3-adrenergic-receptor-agonist-for-the-treatment-of-overactive-bladder
#20
Gian Marco Rosa, Danilo Baccino, Alberto Valbusa, Carolina Scala, Fabio Barra, Claudio Brunelli, Simone Ferrero
Overactive bladder (OAB) syndrome is common in the general population, particularly in elderly patients. Antimuscarinic drugs (AMs) are considered the mainstay pharmaceutical treatment of OAB whereas β3-adrenoceptor agonists, such as mirabegron, represent a good alternative. Owing to the important role of muscarinic and β3 receptors in cardiovascular (CV) tissue and to the fact that OAB patients often have CV comorbidities, the safety-profile of these drugs constitute an important challenge. Area covered: The aim of this review is to evaluate the CV effects of AMs and mirabegron in OAB...
May 2018: Expert Opinion on Drug Safety
keyword
keyword
7718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"